Inflazyme Presents Mixed Asthma Drug Results
Posted on: Tuesday, 30 January 2007, 12:00 CST
Inflazyme has said that analysis of preliminary results from a study of its asthma drug suggests that there were substantial improvements in asthma control but no difference compared to the placebo group.
In the phase IIa study, the primary endpoint was an expected improvement in AQLQ compared to placebo and the secondary endpoints incorporated measures of asthma control.
"The profile and magnitude of the placebo response is extremely surprising and merits further examination," said Dr Kevin Mullane, CEO and president of Inflazyme Pharmaceuticals.
"We are currently conducting a validation review process of the full trial. We expect to report on the outcome of this within the next two to three weeks."
The company is also expecting to report this quarter on the results of IPL455,903, a non-emetic PDE4 inhibitor which is currently being tested in a phase IIa clinical study in age-associated memory impairment.
Source: Datamonitor
Related Articles
- Canada studies asthma drug Xolair risks
- Anti-aging product improves wrinkles
- Global Health Research Foundation Awarded $25,000 Grant From Westly Foundation to Study Asthma in California's Central Valley
- Study: Asthma Linked to PTSD
- Study: Asthma Treatment Episodic
- Study: Asthma Patients Prefer Fast Relief
- LAB International Asthma Study Produces Promising Results
- Sugar cane extract same as placebo: study
- What Drug Safety Studies Found
- Study: Asthma Among U.S. Youth Severe
 |
 |
User Comments (0)
RSS Feeds